Demonstrating efficacy of new drugs to treat this disease is difficult in small trials, conducted in people without high risk of progression to severe COVID, who are excluded from investigative, placebo-controlled trials. The widespread availability of vaccination as well as immunity due to prior infection with SARS-CoV-2 contribute to challenges in demonstrating clinical efficacy in these trials. ( “The Drug doesn’t work when the Symptoms are Mild. It probably works when it’s more Severe / when it’s Life Threatening)…. Why would you Test on Mild Symptoms. Appears a Total Stuff UP.
BIT Price at posting:
1.9¢ Sentiment: Buy Disclosure: Held
